Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors.
Khanh T DoGeraldine O'Sullivan CoyneJohn L HaysJeffrey G SupkoStephen V LiuKristin BeebeLen NeckersJane B TrepelMin-Jung LeeTomoko SmythCourtney GannonJennifer HedglinAlona MuzikanskySusana CamposJohn LyonsPercy IvyJames H DoroshowAlice P ChenGeoffrey I ShapiroPublished in: Cancer chemotherapy and pharmacology (2020)
Combined onalespib and AT7519 is tolerable, though below monotherapy RP2D. Promising preliminary clinical activity was seen. Further benefit may be seen with the incorporation of molecular signature pre-selection. Further biomarker development will require the assessment of the on-target impact on relevant client proteins in tumor tissue.